• A Pan-European leader in clinical healthcare software is born, with leadership in Italy, Germany, Austria and France and over 3,500 employees

• This is an important step for the European consolidation of the sector

The Dedalus Group, a leading European company, and one of the worldwide main ones, active in clinical healthcare information systems to support clinical professionals and organizations in order to improve their care quality level according to an economic and financial sustainability approach, announces that it has completed the acquisition of part of Agfa HealthCare (Agfa-Gevaert Group) IT business for the healthcare sector.

Ardian, which invested in Dedalus in 2016, will hold a stake of approximately 75% after the transaction.

The subject of the agreement is the acquisition of German, French, Austrian, Swiss and Brazilian activities related to clinical, diagnostic and hospital management software (HCIS) and related to IT imaging systems (PACS-RIS of radiology, cardiology, etc.) for a total enterprise value of € 975 million.

Dedalus, long-lasting leader in clinical healthcare software business in Italy and one of the leading players in Europe, with a unique industrial capacity in the sector, a deep knowledge of current processes and the ability to anticipate future needs thanks also to interaction, is now the largest company in the sector with 5,000 Hospitals, 5,000 laboratories and over 2 million professionals who treat hundreds of millions of patients every day.  The Group also promotes the consolidation of the business in Europe, positioning itself among the leading companies in the sector worldwide with a presence in over 30 countries worldwide, a leading position in Italy, Germany, Austria and France, and a total turnover of approximately 470 million euros achieved by over 3,500 professionals.

Giorgio Moretti, Chairman of Dedalus Holding, commented: “Today marks the end of a long path that Dedalus started in 2006, first consolidating the clinical-healthcare software sector in Italy, then in France and today at European level. I am really proud of Dedalus as an Italian company which has been able to promote the birth of what was indispensable for the European market: a champion in the sector able to compete globally. “I am proud also because we are closing such a relevant deal despite the difficult period we are living in due to health emergency and lockdown which did not stop us, thanks to the commitment of our management. Dedalus’s objective has always been to anticipate the evolution of medical science and all the correlated technologies, not only IT, in order to provide our clients with the best tools to improve the quality of prevention, diagnosis and treatment. The target of our strategic thinking is always the patient. Our overall vision and global knowledge of healthcare systems will allow us to act as an aggregator with the sector in order to provide our clients with an even better service, both in Europe and, starting from today, also in Brazil. This important path has been made possible thanks to our financial and strategic partner Ardian who has been supporting us for years”.

“When we invested in Dedalus almost five years ago, we saw all the potential of this Italian excellence and the role it could and should play in the important consolidation process of the clinical healthcare software sector in Europe,” says Yann Chareton, Managing Director of Ardian Buyout. “Through this important acquisition, we have created a leading player in a sector which has never been so fundamental like today because it offers the most innovative and technologically advanced tools to improve the diagnosis and treatment of patients within hospitals and medical facilities in general. We do believe in this growth project that is why we have decided to invest again in the company, reaching 75%”.


Founded in 1982 in Florence, Dedalus, with over 2.000 employees, of which 1.200 in Italy, 550 in France and teams in 25 countries, is an international industrial group in the healthcare software industry specialized in the segment of diagnostic and clinical management solutions (HCIS), GPs and Primary care management, Interoperability and Population health management.
In 2016, the European Private Equity Fund Ardian acquired the 60% of the Dedalus Group boosting its international expansion and strengthening the R&D activities, which is now composed by more than 600 people.

Today, Dedalus exploits the full functional coverage of all ICT needs of any healthcare system, not limited to hospital systems, both public and private. In the last three years, Dedalus has totally renewed its offering, by addressing the state of art of paradigm in terms of technology and functionalities to anticipate the evolution of the clinical practice at the base of the change management of different healthcare system that in many countries are rethinking their organizations.

With more than 130 million euros of revenues in Italy, more than 60 million euros in France and globally more than 210 million euros, Dedalus is one of the leading global players in the sector and holds a leading position in Europe.


The Agfa-Gevaert Group is a leading company in imaging technology and IT solutions with over 150 years of experience. The Group holds four divisions: Radiology Solutions, HealthCare IT, Digital Print & Chemicals and Offset Solutions. They develop, manufacture and market analogue and digital systems for the healthcare sector, for specific industrial applications and for the printing industry.
The Agfa-Gevaert Group’s headquarters and parent company are located in Mortsel, Belgium. The Group’s largest production and research centers are located in Belgium, the United States, Canada, Germany, France, the United Kingdom, Austria, China and Brazil. The Group is commercially active worldwide through wholly owned sales organizations in more than 40 countries. In countries where it does not have its own sales organization, the market is served by a network of agents and representatives. In 2019, the Group realized a turnover of 2,239 million Euro.


Ardian is a world-leading private investment house with assets of US$96bn managed or advised in Europe, the Americas and Asia. The company is majorityowned by its employees. It keeps entrepreneurship at its heart and focuses on delivering excellent investment performance to its global investor base. Through its commitment to shared outcomes for all stakeholders, Ardian’s activities fuel individual, corporate and economic growth around the world. Holding close its core values of excellence, loyalty and entrepreneurship, Ardian maintains a truly global network, with more than 680 employees working from fifteen offices across Europe (Frankfurt, Jersey, London, Luxembourg, Madrid, Milan, Paris and Zurich), the Americas (New York, San Francisco and Santiago) and Asia (Beijing, Singapore, Tokyo and Seoul). It manages funds on behalf of around 1,000 clients through five pillars of investment expertise: Fund of Funds, Direct Funds, Infrastructure, Real Estate and Private Debt.

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)